A detailed history of Axq Capital, LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 52,590 shares of EXEL stock, worth $1.87 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
52,590
Previous 59,629 11.8%
Holding current value
$1.87 Million
Previous $1.34 Billion 1.85%
% of portfolio
0.41%
Previous 0.31%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.96 - $27.6 $154,576 - $194,276
-7,039 Reduced 11.8%
52,590 $1.36 Billion
Q2 2024

Aug 13, 2024

BUY
$20.34 - $23.73 $948,433 - $1.11 Million
46,629 Added 358.68%
59,629 $1.34 Billion
Q1 2024

May 14, 2024

BUY
$20.17 - $23.93 $262,210 - $311,090
13,000 New
13,000 $308 Million
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $253,232 - $302,442
13,300 New
13,300 $291 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Axq Capital, LP Portfolio

Follow Axq Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.